Article

Mutations at Codon 641 of Exon 16 of EZH2 in Circulating Tumor DNA: A Biomarker for Relapse in Patients With Diffuse Large B-cell Lymphoma Treated With the R-CHOP Scheme.

2022-01-07

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> The epigenetic regulator EZH2 is a subunit of the polycomb repressive complex 2 (PRC2), methylates H3K27, resulting in transcriptional silencing. The mutation at Y646 amino acid in the <italic>EZH2</italic> gene is mutated in up to 40 % of B-cell lymphomas. <bold>Methods:</bold> We compared the presence of exon 16 <italic>EZH2</italic> mutations in tumor samples...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d66f3a4a-40cc-5aa3-a447-a217b2626c50
DOI: 10.21203/rs.3.rs-1190066/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mutations at Codon 641 of Exon 16 of EZH2 in Circulating Tumor DNA: A Biomarker for Relapse in Patients With Diffuse Large B-cell Lymphoma Treated With the R-CHOP Scheme.DOI 10.21203/rs.3.rs-1190066/v1Read

ct-DNA is useful to diagnose mutations at codon 641 of exon 16 of EZH2, which is a biomarker for relapse in patients with Diffuse Large B-cell Lymphoma treated with the R-CHOP scheme.Semantic proximity Read

A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.Semantic proximity Read

MIR4435-2HG as a Novel Predictive Biomarker of Chemotherapy Response and Death in Pediatric B-cell AllSemantic proximity Read

Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?Semantic proximity Read

Comprehensive Analysis of Eph-Ephrin as Novel DLBC Biomarkers for Molecular Subtyping and the Predictability in Prognosis and Drug ResponseSemantic proximity Read

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.Semantic proximity Read

Diffuse large B-cell lymphoma with combinedTP53mutation andMIR34Amethylation: Another “double hit” lymphoma with very poor outcome?Semantic proximity Read

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.Semantic proximity Read

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.Semantic proximity Read

A53-Adapted Decitabine-Containing R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Defined by LymphGen: Preliminary Results of a Prospective Proof-of-Concept StudySemantic proximity Read

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasmsSemantic proximity Read

Consolidative breast radiotherapy and prophylactic high-dose methotrexate are important first-line treatments for primary breast diffuse large B-cell lymphoma patients treated with R-CHOP-like regimensSemantic proximity Read